Page 22«..10..21222324..3040..»

Global Contrast Agents for MRI Market 2020 COVID 19 Updated Analysis By Top Key Players GE Healthcare (US), Bracco Imaging (Italy), Bayer HealthCare…

§ May 31st, 2020 § Filed under Nano Medicine Comments Off on Global Contrast Agents for MRI Market 2020 COVID 19 Updated Analysis By Top Key Players GE Healthcare (US), Bracco Imaging (Italy), Bayer HealthCare…

Global Contrast Agents for MRI Industry Competitive Analysis -Forecast and Historical Market Analysis by Key Market Segments

The globalContrast Agents for MRI marketreport is updated and is published by theMarket Research Store. Detailed information about the Contrast Agents for MRI market is included which is updated according to the recent outbreak of COVID-19. The data that is provided in the report study consists of historical data from 2016 to 2019 and also forecasts the further market conditions from 2020 to 2026. The Contrast Agents for MRI market report study consists of over 150 pages and has over 30 tables and above 20 figures.

Request Free Sample Copy of Contrast Agents for MRI Market Research Report@http://www.marketresearchstore.com/report/global-contrast-agents-for-mri-market-report-2018-383604#RequestSample

All the market players that are operating in the Contrast Agents for MRI market is incorporated. Some of the major players that are included within the report areGE Healthcare (US), Bracco Imaging (Italy), Bayer HealthCare (Germany), Guerbet (France), Lantheus (US), Daiichi Sankyo (Japan), Unijules Life Sciences (India), J.B. Chemicals and Pharmaceuticals (India), Spago Nanomedicine (Sweden), Taejoon Pharm (South Korea), Jodas (India), Magnus Health (India). All the details about the organization are included for having clear idea about the market competitiveness.

The Contrast Agents for MRI market report consists of market definition and overview. The target audience for the market is also included for better understanding the market scenario. The research analysts have conducted several primary and secondary researches in order to obtain the numerical for the Contrast Agents for MRI market. The compound annual growth rate of the Contrast Agents for MRI market is revised and updated in the report study. This is owing to the changed market conditions amidst COVID-19. Several research methodologies and tools were used for further validating the data that was obtained through these researches.

Read Detailed Index of full Research Study at@::http://www.marketresearchstore.com/report/global-contrast-agents-for-mri-market-report-2018-383604

The growth factors of the Contrast Agents for MRI market are included along with detailed information about the market drivers. The market restraints are also included along with supporting facts. In the coming years, the Contrast Agents for MRI market will have to face several challenges but there will also be opportunities for the market to grow in the coming years. All these factors are also included in the study.

The Contrast Agents for MRI market segmentation includes{Barium-based Contrast Media, Iodinated Contrast Media, Gadolinium-based Contrast Media, Microbubble Contrast Media}; {Radiology, Interventional Radiology, Interventional Cardiology}. In-depth study has been conducted about each and every segment of the market. The information in the report is depicted in subjective form as well as using tables and pictorial representations. This aids for better understanding of the Contrast Agents for MRI market. The regional representations are also included. Global market analysis, region-wise and country-wise market analysis is also included within the dossier.

If Any Inquiry of Contrast Agents for MRI Report:http://www.marketresearchstore.com/report/global-contrast-agents-for-mri-market-report-2018-383604#InquiryForBuying

The key highlights of the report:

1) Market driver, barriers, opportunities, and challenges 2) Industry development 3) Key regulations and mandates 4) Patent analysis 5) Value chain analysis 6) Porters five forces model 7) PESTLE and SWOT analysis 8) Competitive landscape 9) Investment opportunity analysis 10) List of distributors/traders and buyers

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19. (*If you have any special requirements, please let us know and we will offer you the report as you want.)

View post:
Global Contrast Agents for MRI Market 2020 COVID 19 Updated Analysis By Top Key Players GE Healthcare (US), Bracco Imaging (Italy), Bayer HealthCare...

Read the Rest...

Winters | Facing the challenge of COVID-19 | Columnists – East Oregonian

§ May 31st, 2020 § Filed under Nano Medicine Comments Off on Winters | Facing the challenge of COVID-19 | Columnists – East Oregonian

Life on planet Earth has been upended by a microscopic speck. Since a vaccine designed to immunize, or a drug hoping to cure COVID-19 are not yet available, the best advice that 21st century medicine and technology currently offer is hand washing and social distancing.

These steps are, in fact, very effective in reducing disease, yet we can do more than merely wait for an uncertain solution. Past experience has taught us that basic measures, including sanitation, good nutrition and personal hygiene are the most important tools in preventing the spread of a pandemic. We can build on this knowledge to help our bodies do what they are designed to do address challenges and remain healthy.

Viruses are sub-microscopic specks of genetic information, found everywhere life exists. Viruses infect everything people, animals, plants and even other microbes. They constantly change, or mutate, to improve their chances of survival. Viruses are biological ninjas; they are merely stealthy packets of genetic information that require living cells to do their work. Viruses invade cells and take over the machinery, commanding the cell to make more viruses, all while hiding inside the cell where the immune system cant detect them. Yet, over 99% of the million known viral strains are harmless to people, and some are even beneficial. Viruses and other microbes have co-existed with humans for millions of years.

The human body was made to survive viral challenge; your own body has endured countless invasions from viruses, bacteria and other microbes in its lifetime. The new coronavirus is merely the latest variation. We are swimming in a sea of microbes; they are all around us, on our skin and in our guts. This is business as usual for the body!

Healthy cells are much more resistant to disease than distressed cells, and many avenues exist to improve cells inborn immune defenses. Circulation of the blood and lymphatic systems deliver immune factors and nutrients to cells, while removing wastes and toxins.

Help your circulatory system do its job through staying well-hydrated (drink half your body weight in ounces of water daily), deep breathing, movement, stretching and ending hot showers with a cold rinse.

Regular physical exertion improves immunity, while also stabilizing energy, moods, blood sugar, and hormone levels. Fresh whole foods (versus packaged) provide vitamins (especially vitamin D), minerals and other nutrients required for efficient immune function.

Fresh air, full sunlight, clean water, plenty of sleep, and good mental health are all key to stronger defenses.

Medicinal plants are another avenue to explore to enhance immune function; some that have been successfully used for centuries are garlic, licorice, echinacea, curcumin and ginseng. These are but a few examples of plants that fight viral infection, pneumonia and inflammation directly and indirectly.

Remember, the main variables which determine whether or not illness occurs are the strength of the pathogen (i.e. COVID) versus the strength of the host (your name here). Now is a good time to strengthen the host.

Getting sick is a test for the body. Every day, we are exposed to many challenges to our health: viruses, poor sleep, stress, inactivity, other people, moods, etc. A healthy mind and body will get stronger with each new challenge, so long as the challenge is not too great.

For example, moderate exercise may be tiring, but eventually makes you stronger. Learning a new skill is challenging, but can be rewarding. Likewise, your immune system gets smarter and stronger when it overcomes an illness. The key is to help it win.

Improve your resistance by improving your health, and feel better every day doing it. Take good care of yourself in every way you can.

John Winters is a naturopathic physician, who recently retired after operating a practice in La Grande since 1992.

See the original post here:
Winters | Facing the challenge of COVID-19 | Columnists - East Oregonian

Read the Rest...

The allergies live on – Martinsburg Journal

§ May 31st, 2020 § Filed under Nano Medicine Comments Off on The allergies live on – Martinsburg Journal

The preventative measures weve been taking to limit our exposure to The Virus have uncanny similarities to how some of us have to protect ourselves against another microscopic danger to our bodies allergens. People with food, topical or airborne allergies have to maintain many of the same precautions that weve been advised, or been ordered, to practice in the last two months; social distancing, using PPE, testing, frequent hand-washing, and contact tracing.

Allergies are classified as a disease, defined as a number of conditions caused by hypersensitivity of the immune system to typically harmless substances in the environment.

Some people outgrow their allergies or tame them with medications and desensitizing techniques, but anyone can develop them later in life. Some type of allergy affects nearly half of all Americans today. One popular theory for that increase is that our Sanitized Western Lifestyle doesnt allow children to develop antibodies to microbes. Others blame plastics and their many chemical components.

Allergies force people to self-quarantine from substances that can literally kill them. Those who are extremely sensitive can detect the antigen from several feet away from its source, so social distancing is a life-long pattern for them. There is no vaccine, as an example, for the common peanut allergy. Peanut butter the cheap childhood staple that is high in protein and keeps forever is no longer served in many school cafeterias, nor are peanuts included with snacks on flights; like a virus, nut particles can travel through the air, and traces of its oils can linger on surfaces indefinitely.

Contamination at food plants is hard to control, so manufacturers cant 100% guarantee that, for example, a peanut wont make its way into an almond bar. With the proliferation of soy-based additives to foods, its nearly impossible to isolate exactly what causes a reaction. Eggs laid by hens that were fed soy chicken feed, pass trace amounts of it into their eggs. Vegetable broth usually contains soy, and the ambiguous ingredient natural flavors usually contains soy derivatives. Vegetable oil might include soybean oil, and even though its safe for some, others find it problematic depending on the method of extraction.

The USDA maintains a website (www.foodsafety.gov) for updates on food recalls for allergy contaminations; you can sign up for notifications, but be warned youll get a lot of emails.

People are noting that their Hay-Fever flares up at odd times, not realizing that leaf blowers, which once were limited to the autumn months but are now used throughout the year, dredge up spores and microbes from the soil along with pesticides and oil-based contaminants from automobiles. Some have resorted to wearing face masks during pollen season and when lawn care is being done. Asthma or RAD (Reactive Airway Disease) is exacerbated by the indoor air pollution we have created with our pets, cleaning substances, and smoking. The allergy to man-made chemicals has its own category: MCS, or Multiple Chemical Sensitivity. The biggest culprits are synthetic fragrances, but thousands of oil-based products can cause headaches, nausea, and flu-like symptoms. And those are literally everywhere in the world, no matter where you go.

Medication allergies can also be puzzling; it may be the buffers, dyes, and capsule coatings that cause reactions. The leading manufacturer of the anti-allergy medicine diphenhydramine adds a known allergen, Red Dye#40, to tint the pills with a lovely shade of pink. That can cause a drug reaction itchier than the poison ivy rash you took it for in the first place.

Contact-tracing is something all allergic people do instinctively, trying to track down the source of symptoms that may appear with no obvious trigger. They have to be their own detectives, sometimes keeping a symptom diary. Allergists generally suggest that patients get a patch test, which involves exposing an area of skin to substances that might be the source of the reaction. The test is itchy and usually expensive even with insurance. Like the virus test, so far, they are often unreliable due to false positives.

People with allergies inhabit a world much like weve all lived in since March, with constant surveillance, limiting restaurant dining because food ingredients cant be verified, washing their hands just in case theyve touched a nut or making sure they dont kiss anyone who just ate one, or asking friends to ditch their perfumes and scented laundry products. All their precautions, by the way, are inconvenient, imperfect, and can impose on the personal freedoms of themselves and at times, others around them.

This virus will eventually die out, and well return to a more casual lifestyle without these interventions. And thats too bad; some of those behaviors would make us healthier and protect us from every-day communicable diseases, or from allergies any of us could develop or from the next pandemic.

History tells us that there is always another one just waiting to happen, no matter what we do, and when we least expect it.

Carol Williams lives in Berkeley County, and is a US Army veteran and former ER nurse. Her archived columns from the Journal are published in a book titled the Age of Uterine Law. She can be contacted through her website, http://www.anothercarolwilliams.com.

The rest is here:
The allergies live on - Martinsburg Journal

Read the Rest...

The impact of the coronavirus on the Pre-Owned Medical Devices Market: Biggest Innovation to Boost Global Growth Rate 2020 Evolving Technology, Market…

§ May 31st, 2020 § Filed under Nano Medicine Comments Off on The impact of the coronavirus on the Pre-Owned Medical Devices Market: Biggest Innovation to Boost Global Growth Rate 2020 Evolving Technology, Market…

Global Pre-Owned Medical Devices Market Analysis

The recent report presented by MRRSE on the global Pre-Owned Medical Devices market is an in-depth analysis of the overall prospects of the Pre-Owned Medical Devices market in the upcoming years. The data collected from credible primary and secondary sources is accurately represented in the report backed up by relevant figures, graphs, and tables. The market study covers the impact of the COVID-19 pandemic on the growth prospects of the global Pre-Owned Medical Devices market. The report includes a quantitative and qualitative analysis of the various aspects of the market by collecting data from the key participants in the Pre-Owned Medical Devices market value chain.

The report reveals that the global Pre-Owned Medical Devices market is set to grow at a CAGR of ~XX% over the forecast period (2019-2029) and surpass the value of ~US$XX by the end of 2029. The presented study also includes a thorough analysis of the micro and macroeconomic factors, regulatory framework, and current trends that are expected to influence the growth of the Pre-Owned Medical Devices market during the assessment period.

Request Sample Report @https://www.mrrse.com/sample/2981?source=atm

Vital Information Enclosed in the Pre-Owned Medical Devices Market Report:

Important Queries Addressed in the Report

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/2981?source=atm

Pre-Owned Medical Devices Market Segmentation

The market study put forward by MRRSE segments the global Pre-Owned Medical Devices market to offer a microscopic understanding of the various aspects of the Pre-Owned Medical Devices market. The Pre-Owned Medical Devices market is segmented on the basis of region, product type, end-user, and more.

The study offers a Y-o-Y growth projection of each market segment and sub-segment over the stipulated timeframe of the study.

segmented as follows:

Link:
The impact of the coronavirus on the Pre-Owned Medical Devices Market: Biggest Innovation to Boost Global Growth Rate 2020 Evolving Technology, Market...

Read the Rest...

Letter to the Editor: On masks and COVID-19 – Daily Bulldog

§ May 31st, 2020 § Filed under Nano Medicine Comments Off on Letter to the Editor: On masks and COVID-19 – Daily Bulldog

There are some indisputable fact about COVID-19:

1. The disease is real and people are dying from it. Over 1.6 million Americans have been infected and almost 100,000 have died since February. 2. There is no drug that can cure the infection once someone has it. There are some drugs used in the critical care setting which may improve survival but none are proven yet. Treatment is mostly supportive until the body fights off the infection itself. 3. Sometimes the immune system gets out of control and causes complications worse than the initial infection. 4. There is no vaccine yet to prevent or weaken infection. 5. Infected individuals are contagious to others even before they have symptoms themselves. Microscopic droplets containing virus come out of an infected persons nose and mouth when they talk, sneeze, cough, sing, etc.and can travel at least six feet in the air. 6. Masks have been shown to reduce the number of these droplets which escape. The Presidents COVID response coordinator, Dr. Birx, has this to say about masks: "What we have said to people is there is clear scientific evidence now, by all the droplet experiments that happened, and that others have done, to show that a mask does prevent droplets from reaching others," Birx said on "Fox News Sunday" when asked what she would tell people who say they have a right not to wear a mask in public.

"Out of respect for each other, as Americans that care for each other, we need to be wearing masks in public when we cannot social distance," she said.

Im not sure how wearing a mask in public has become politicized but quarantine, social distancing, and wearing a mask in public are the only current ways to limit the spread of the virus and open up our economy without risking even more loss of life. I urge you all to respect your fellow Mainers by wearing a mask in public if social distancing is not possible.

Jay Naliboff MD Chesterville

Read this article:
Letter to the Editor: On masks and COVID-19 - Daily Bulldog

Read the Rest...

Abu Dhabi doctor’s first-hand account on how UAE medics are battling COVID-19 – Gulf News

§ May 31st, 2020 § Filed under Nano Medicine Comments Off on Abu Dhabi doctor’s first-hand account on how UAE medics are battling COVID-19 – Gulf News

Dr Ken Dittrich with other staff members at Sheikh Khalifa Medical City Image Credit: Supplied

Abu Dhabi: Because COVID-19 is brought about by a novel coronavirus, the evolving nature of its treatment is challenging for even the most seasoned medical professionals.

Dr Ken Dittrich has completed nearly 40 years of work in emergency medicine, yet he is unequivocal when he says that he has seen nothing like the COVID-19 outbreak.

Dr Ken Dittrich

I like to be on frontlines, making first contact with the patient, problem-solving and investigating their symptoms in a manner that is critical and can often be lifesaving. This novel coronavirus is exceptionally challenging. It isnt just a respiratory illness [anymore]; were even seeing developing symptoms like blood clotting, clots to lungs, dual diagnoses and cytokine storms, the consultant emergency physician at Sheikh Khalifa Medical City (SKMC), told Gulf News.

Still, like hundreds of healthcare professionals, Dr Dittrich dons his Personal Protective Equipment (PPE) every day and heads out to battle the microscopic enemy that has altered the shape and form of entire health systems around the world. The Canadian-born doctor has been heading up the emergency medicine department at SKMC for the past 17 years, and says healthcare workers are having to learn on the job every day as they fight the coronavirus.

As a medical professional, I find this disease trying because of the continual education its treatment entails, the volume of cases cropping up and even the amount of ventilation [healthcare facilities] need to provide, Dr Dittrich said.

His testimony reinforces just how fast and greatly the outbreak, and its related treatment protocols, have changed since the coronavirus came to light just five months ago. From taking in every patient who tested positive, hospitals are now only able to admit those who need medical attention due to the severity of their symptoms.

We recognised that the coronavirus would come to the UAE because of its position as a travel hub, and the first two patients we saw had travel history to China and Italy. At that time, we were admitting all patients who tested positive. But then, the volumes kept increasing very rapidly, Dr Dittrich said.

Another illustration of this is the protocol on invasive ventilation.

The early trend [and protocol] was to put patients on ventilation early. But as more and more cases emerged in [Europe and the United States], the recommendation changed to put off intubation for as long as possible. [Doctors were finding that] the device can put high pressure in the lungs, thereby causing further injury, Dr Dittrich said.

Now, physicians try all other interventions before proceeding to invasive ventilation, including respiratory exercises, nasal canulas to provide oxygen, and non-invasive ventilation through face masks with attached oxygen reservoirs.

The doctor explained that normal oxygen saturation is 94 per cent or higher. In patients with minor cases of COVID-19 in the UAE, the saturation level ranges from 88 per cent to 94 per cent. When this level drops to 60 or 70 per cent, patients may be alert, but they struggle to breathe and talk.

Fortunately, 80 per cent of cases are mild or asymptomatic. Only 20 per cent require hospitalisation for oxygen therapy, and only five per cent are potential life-threatening cases, such as those experiencing a cytokine storm, Dr Dittrich said.

And again, not all of the people with severe cases of coronavirus need to be intubated immediately.

But they do require intensive care, with medical professionals working around the clock to stabilise patients.

One of the most difficult cases I have seen recently is that of a 50-year-old patient who came in last week. He had come to the hospital during the previous physicians shift, and had presented with COVID-19 pneumonia. He then experienced several cardiac arrest episodes, as well as massive blood clots to the lungs, and was never stable enough to even be moved to the Intensive Care Unit, Dr Dittrich said.

He and his team worked all night long to tend to the patient.

Thankfully, he is still with us, and I hope he will recover, the doctor said.

Due to the nature of his job, Dr Dittrich is not often able to follow up on the patients he sees. But he knows that many of them, including the ones who were hospitalised in early March, are still under treatment, with some even receiving convalescent plasma therapy.

The lengthy treatment course means that entire hospitals around the world have been transformed into facilities dedicated to the treatment of COVID-19. According to Dr Dittrich, all of SKMCs 600 beds are being made available for patients with coronavirus, including for those who require hospitalisation for other medical conditions but are also testing positive for COVID-19.

And he was unambiguous that a COVID-19 case can be trying.

Dr Ken Dittrich

We see dire cases in the ER, including motor vehicle trauma, cardiac arrest, sepsis and cancer complications. Then there are patients with major burns, which I find the grimmest to deal with because I can empathise with the lifelong struggle the patient will have to face. But with COVID-19, every part of the care is important, Dr Dittrich said.

To that end, the doctor gave a shout-out to every spoke of the [healthcare] wheel, including the nurses who toil in healthcare facilities and the vast array of support personnel who have risen to the occasion.

As emergency physicians, we do a lot. But you cannot discount the hospital administration that supports our work and provides the PPE, the cleaning staff who disinfect contaminated rooms, or the security personnel, the respiratory technicians and the kitchen staff. It really is a team effort, Dr Dittrich said.

Then there are the protective mechanisms put in place by the government. The economic and mental health impacts of this outbreak cannot be discounted, and [it is reassuring] that the government is looking after us so well, he added.

For his part, the 62-year-old doctor is continuing to train at home with his wife, and eating healthy.

[Im in] an at-risk group, I know, but my wife and I do our best to stay fit. And then they test us at the hospital every week, he said.

He is also clearly staying positive: when asked if he would have reconsidered his profession if he had known he would face a pandemic, Dr Dittrich didnt miss a beat.

I am glad to be able to contribute to this crisis. I see only the critical cases, but I know the entire community is making huge sacrifices. So as they say, we are going to get through this together, he said.

Follow this link:
Abu Dhabi doctor's first-hand account on how UAE medics are battling COVID-19 - Gulf News

Read the Rest...

Potential Impact of COVID-19 on Rise in Prevalence of Depression that Boosts the Growth of Medical Anesthesia Agent, Global Market In Industry – Cole…

§ May 31st, 2020 § Filed under Nano Medicine Comments Off on Potential Impact of COVID-19 on Rise in Prevalence of Depression that Boosts the Growth of Medical Anesthesia Agent, Global Market In Industry – Cole…

The Medical Anesthesia Agent, Global market research encompasses an exhaustive analysis of the market outlook, framework, and socio-economic impacts. The report covers the accurate investigation of the market size, share, product footprint, revenue, and progress rate. Driven by primary and secondary researches, the Medical Anesthesia Agent, Global market study offers reliable and authentic projections regarding the technical jargon.All the players running in the global Medical Anesthesia Agent, Global market are elaborated thoroughly in the Medical Anesthesia Agent, Global market report on the basis of proprietary technologies, distribution channels, industrial penetration, manufacturing processes, and revenue. In addition, the report examines R&D developments, legal policies, and strategies defining the competitiveness of the Medical Anesthesia Agent, Global market players.The report on the Medical Anesthesia Agent, Global market provides a birds eye view of the current proceeding within the Medical Anesthesia Agent, Global market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Medical Anesthesia Agent, Global market and offers a clear assessment of the projected market fluctuations during the forecast period.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2660824&source=atm

Market Segment Analysis The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type, the Medical Anesthesia Agent market is segmented into Anesthetic Narcotic Drugs

Segment by Application Hospital Clinic Other

Global Medical Anesthesia Agent Market: Regional Analysis The Medical Anesthesia Agent market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026. The key regions covered in the Medical Anesthesia Agent market report are: North America U.S. Canada Europe Germany France U.K. Italy Russia Asia-Pacific China Japan South Korea India Australia Taiwan Indonesia Thailand Malaysia Philippines Vietnam Latin America Mexico Brazil Argentina Middle East & Africa Turkey Saudi Arabia U.A.E

Global Medical Anesthesia Agent Market: Competitive Analysis This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.

The major players in global Medical Anesthesia Agent market include: Pfizer Baxter International Merck AstraZeneca B-Braun Hengrui Medicine Piramal Critical Care Lunan Pharmaceutical Group Fresenius AG Jiangsu Nhwa Pharmaceutical Co., Ltd. Humanwell Healthcare Xian Libang Enterprises Maruishi Endo Pharmaceuticals Hikma Pharmaceuticals Organon Roche Pharma Abbott

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2660824&source=atm

Objectives of the Medical Anesthesia Agent, Global Market Study:To define, describe, and analyze the global Medical Anesthesia Agent, Global market based on oil type, product type, ship type, and regionTo forecast and analyze the Medical Anesthesia Agent, Global market size (in terms of value and volume) and submarkets in 5 regions, namely, APAC, Europe, North America, Central & South America, and the Middle East & AfricaTo forecast and analyze the Medical Anesthesia Agent, Global market at country-level for each regionTo strategically analyze each submarket with respect to individual growth trends and their contribution to the global Medical Anesthesia Agent, Global marketTo analyze opportunities in the market for stakeholders by identifying high growth segments of the global Medical Anesthesia Agent, Global marketTo identify trends and factors driving or inhibiting the growth of the market and submarketsTo analyze competitive developments, such as expansions and new product launches, in the global Medical Anesthesia Agent, Global marketTo strategically profile key market players and comprehensively analyze their growth strategiesThe Medical Anesthesia Agent, Global market research focuses on the market structure and various factors (positive and negative) affecting the growth of the market. The study encloses a precise evaluation of the Medical Anesthesia Agent, Global market, including growth rate, current scenario, and volume inflation prospects, on the basis of DROT and Porters Five Forces analyses. In addition, the Medical Anesthesia Agent, Global market study provides reliable and authentic projections regarding the technical jargon.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2660824&licType=S&source=atm

After reading the Medical Anesthesia Agent, Global market report, readers can:Identify the factors affecting the Medical Anesthesia Agent, Global market growth drivers, restraints, opportunities and trends.Examine the Y-o-Y growth of the global Medical Anesthesia Agent, Global market.Analyze trends impacting the demand prospect for the Medical Anesthesia Agent, Global in various regions.Recognize different tactics leveraged by players of the global Medical Anesthesia Agent, Global market.Identify the Medical Anesthesia Agent, Global market impact on various industries.

View post:
Potential Impact of COVID-19 on Rise in Prevalence of Depression that Boosts the Growth of Medical Anesthesia Agent, Global Market In Industry - Cole...

Read the Rest...

Coronavirus (COVID-19) Impact On Global Inflammatory Market 2020 Analysis By Top Key Players | Merck, Novartis, Thermo Fisher Scientific, Cell…

§ May 31st, 2020 § Filed under Nano Medicine Comments Off on Coronavirus (COVID-19) Impact On Global Inflammatory Market 2020 Analysis By Top Key Players | Merck, Novartis, Thermo Fisher Scientific, Cell…

Inflammatory

TheInflammatory marketreport will give you every microscopic details about the Inflammatory market. It consists of the current trends and the futuristic scope of the market. The details about the Inflammatory market includes the impact of the COVID-19 on the market economics. The lockdown in several regions has severely impacted the business around the world. The Inflammatory research study includes aspects such as the growth factors, limitations of the market, future and current challenges of the market along with the opportunities that will open up for the market based on the current scenario of COVID-19. It has been projected that the Inflammatory market can regain its position owing to the factors such as supportive government regulations and well researched market strategies implemented by the market players. The major market players that are mentioned within this study includeMerck, Novartis, Thermo Fisher Scientific, Cell Signaling Technology, Boditech Med, PHC Holdings, Abbott, Siemens, BG Medicine.

Click Here To Access The Free Sample PDF Report (including COVID19 Impact Analysis, full TOC, Tables and Figures)@https://www.marketdataanalytics.biz/global-inflammatory-market-industry-trends-and-forecast-to-2027-21051.html#request-sample

The research on the Inflammatory market includes use of various trusted research methodologies in order to obtain trusted and precise data about the market. Porters Five force analysis, SWOT analysis, top down approach/ bottom up approach are some of the methods that have been encapsulated in the report. Along with these methodologies the research team has done rigorous primary and secondary research in order to make the information trustworthy.

Main market perceptions consist of the following:

1. The survey of Inflammatory delivers market size and growth rate for the forecast period 2020-2026.

2. It presents detailed understandings into ongoing industry trends, trend prediction, and growth drivers about the Inflammatory.

3. It offers an independent review of market sectors and the regional outlook of Inflammatory.

4. The report provides a detailed overview of the supplier landscape, combative analysis, and key market strategies to gain an advantage on competing companies.

Read Detailed Index of full Research Study at::https://www.marketdataanalytics.biz/global-inflammatory-market-industry-trends-and-forecast-to-2027-21051.html

The contents of the Inflammatory market includes the market definition, target audience influencing and being influenced, market drivers, restraints, opportunities, and challenges. The Inflammatory market is segmented into{Interlukin, C Reactive Protein, Cellular Adhesion Molecule, Tumor Necrosis Factor-a}; {Hospitals, Diagnostic Laboratories, Research Laboratories}along with this major segmentation the report also includes sub-segments of the market to understand the market on a deeper level. The report highlights the futuristic scopes and the alterations needed for the market development.

The major regional segmentation mentioned within the report includes North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. The major countries that are included within the Inflammatory market report are US, Mexico, Australia, India, Germany, Brazil, and others. Every company operating in the Inflammatory market is profiled with precision for better understanding of the current market scenario.

For Any Query Regarding the Inflammatory Market Report? Contact Us at:https://www.marketdataanalytics.biz/global-inflammatory-market-industry-trends-and-forecast-to-2027-21051.html#inquiry-for-buying

Read the rest here:
Coronavirus (COVID-19) Impact On Global Inflammatory Market 2020 Analysis By Top Key Players | Merck, Novartis, Thermo Fisher Scientific, Cell...

Read the Rest...

Bruker : Introduces Breakthrough MALDI-2 Source on timsTOF fleX, and Further Innovations in CCS-Enabled 4D Proteomics on timsTOF – Marketscreener.com

§ May 31st, 2020 § Filed under Nano Medicine Comments Off on Bruker : Introduces Breakthrough MALDI-2 Source on timsTOF fleX, and Further Innovations in CCS-Enabled 4D Proteomics on timsTOF – Marketscreener.com

05/30/2020 | 08:45pm EDT

Bruker Introduces Breakthrough MALDI-2 Source on timsTOF fleX, and Further Innovations in CCS-Enabled 4D Proteomics on timsTOF

MALDI-2 Increases Small Molecule Sensitivity by One or Two Orders of Magnitude New prm-PASEF Workflow for Translational 4D Proteomics Large-Scale, High-Precision Peptide CCS Measurements for Deep Learning Short-gradient dia-PASEF Methods for High Throughput 4D Proteomics Unique CCS-enabled Mobility Offset Mass Aligned (MOMA) for Identification of Isobars 'Run & Done' Novel IP2/GPU Real-Time Search Engine for High-Throughput 4D Proteomics

timsTOF fleXTM ESI/MALDI mass spectrometer

BILLERICA, Massachusetts - June 1st, 2020: At the virtual ASMS 2020 Reboot conference, Bruker Corporation (Nasdaq: BRKR) today announces a major advance in matrix-assisted laser desorption ionization (MALDI) with the launch of the world's first commercial MALDI-2 post-ionization (PI) source, which is now available as an option on the timsTOF fleX ESI/MALDI mass spectrometer. The novel MALDI-2 technology can offer one or two orders of magnitude higher sensitivity for many small molecules and lipids. MALDI-2 increases the applications range of MALDI mass spectrometry and imaging even further.

Moreover, Bruker launches additional unique TIMS/PASEF-enabled 4D proteomics methods that leverage the large-scale, real-time availability of accurate collision cross sections (CCS) for tens of thousands of measured peptides per 4D nanoLC-CCS-MS/MS run. These new methods and software include prm-PASEF, short-gradient dia-PASEF, MOMA, and 'Run and Done' proteomics using a novel GPU-based real-time search engine. In addition to further enhanced peptide, protein and PTM identification, these CCS-enabled innovations allow for sustained, ultra-high sensitivity LFQ performance, and for truly high-throughput methods for 4D proteomics, 4D lipidomics and 4D metabolomics on the exceptionally robust timsTOF Pro platform.

A. SpatialOMx and Translational Mass Spectrometry Imaging on timsTOF fleX

The innovative MALDI-2 PI source increases both the sensitivity and range of applications of MALDI very significantly. MALDI-2 requires a second laser (266 nm) fired orthogonally into the expanding MALDI plume that is generated by Bruker's proprietary primary SmartBeam 3D (355 nm) laser. An optimized flexMatrix formulation is recommended for MALDI-2. The new MALDI-2 source is now available as an option on the timsTOF flex ESI/MALDI instrument.

Professor Klaus Dreisewerd, Leader Section for Biomedical Mass Spectrometry at the University of Muenster in Germany, and the pioneer of MALDI-2, said: 'In the last 35 years, MALDI has become a unique and rapid analytical tool for a wide variety of applications. We developed MALDI-2 to significantly extend the technique by providing much higher sensitivity for small molecules, and the inclusion of chemical classes that did not ionize efficiently with MALDI. The MALDI-2 powered timsTOF fleX will take MALDI to new scientific and analytical frontiers.'

Dr. Michael Easterling, Global MS Imaging Director at Bruker Daltonics, added: 'The growing value of MALDI Imaging and SpatialOMx for tissue-specific models in drug development drives demand for even higher sensitivity and versatility. With its dramatically increased sensitivity and accessible range of chemical classes, the novel MALDI-2 source option can now further enhance mass spectrometry-based, non-targeted tissue analysis.'

Bruker now also offers a MALDI-2 compound reference library for its MetaboScape metabolomics software, which was created during various academic and pharma collaborations. MetaboScape provides automatic analyte annotation within the SCiLS Lab MALDI imaging software, including CCS-algorithms that improve the confidence of annotation for many metabolites, glycans and lipids directly in tissue images.

B. CCS-Enabled 4D Proteomics Innovations on timsTOF Platform prm-PASEF for Translational Quantitative 4D Proteomics

Bruker's revolutionary timsTOF Pro for has been further enhanced by combining PASEF with parallel reaction monitoring (PRM) for label-free quantitative proteomics. This unique mode of prm-PASEF takes advantage of the 4th dimension of separation using TIMS to improve selectivity and sensitivity, combined with the speed of PASEF to increase the number of precursor targets. Working closely with the Skyline team to enable prm-PASEF methods, Skyline software can now analyze the prm-PASEF data and produce quantitative reports.

The group of Prof. Gunnar Dittmar from the Luxembourg Institute of Health and Prof. Antoin Lesur, who both worked on the prm-PASEF workflow development, commented: 'We have been extremely impressed by the early results from prm-PASEF on the timsTOF Pro in our lab. The sensitivity and speed of prm-PASEF already rivals that of PRM methods that have been developed over many years on other platforms.'

Dr. Jarrod Marto, Associate Professor at the Dana-Farber Cancer Institute, Harvard Medical School, and Brigham and Women's Hospital added: 'We have made tremendous progress since initiating co-development of prm-PASEF with the Bruker Team. The unique combination of acquisition speed and integrated ion mobility on the timsTOF Pro enable us to robustly quantify potential biomarker candidates across clinical cohorts. Moreover, real-time adjustment of acquisition parameters with prm-PASEF LIVE will push usability and throughput even further.'

Large-Scale, High-Precision Peptide CCS Measurements for Deep Learning

Peptide collisional cross sections (CCS) measured at large scale and with high precision by the unique TIMS technology deliver added dimensionality for increased confidence of identification in 4D proteomics. A new study by Florian Meier et. al., entitled 'Deep learning the collisional cross sections of the peptide universe from a million training samples', and submitted to bioRxiv, (2020.05.19.102285; doi: doi.org/10.1101/2020.05.19.102285), uses a deep learning training set of 570,000 CCS values measured in 360 LC/MS runs of fractionated digests of five organisms, run on a timsTOF Pro system.

Professor Matthias Mann, Director at the Max Planck Institute of Biochemistry, Germany, commented: 'The size and shape of peptide ions in the gas phase are an under-explored dimension for mass spectrometry-based proteomics. CCS values can now be predicted for any peptide and organism, forming a basis for advanced proteomics workflows that make full use of the additional information.'

Short-gradient dia-PASEF and Mobility Offset Mass Aligned (MOMA) for 4D Proteomics

New short-gradient methods have been developed using the dia-PASEF workflow, which is finding increasing use in many timsTOF Pro labs. Dia-PASEF can provide a meaningful advance in data completeness, and the dia-PASEF workflow is now supported by Bioinformatics Solutions Inc. PEAKS and Biognosys Spectronaut software.

Dr. Lukas Reiter, Chief Technology Officer of Biognosys commented: 'With the Spectronaut 14 launch, we have complete support for the timsTOF Pro: Fast library generation from PASEF and ion mobility calibration for a more specific targeted extraction in Spectronaut. Furthermore, we have added directDIA support for the timsTOF Pro. We are also excited to have a timsTOF Pro in our lab to further speed up our software development for this new and exciting platform.' Dr. Gary Kruppa, Vice President for Proteomics at Bruker Daltonics, added: 'With the launch of prm-PASEF, the growing success of dia-PASEF, and the trend towards shorter gradients that take advantage of the robustness, sensitivity and unmatched duty-cycle of PASEF, the timsTOF Pro provides the capabilities to make 4D proteomics 'translational reality'. Furthermore, the unique MOMA feature of TIMS allows for targeting isobaric precursors at similar retention times for MS/MS acquisition. Having MOMA capability helps improve the depth of coverage using short gradients, and this is important to our translational research proteomics users who are running >50 samples per day per timsTOF Pro.'

'Run & Done' Real-Time Search Developed by Yates Lab for High-Throughput 4D Proteomics

Bruker announces the availability of the proteomic pipeline (IP2) with a GPU-based search engine incorporating the ProLuCID database search tool from the laboratory of Professor John Yates at The Scripps Research Institute based in LaJolla, CA. This unique GPU-based IP2 software has been developed by Dr. Robin Park and allows timsTOF Pro 4D data to be searched in real-time during acquisition, with search results available at the end of the run.

Prof. John Yates III and Dr. Robin Park said: 'The co-evolution of computational advances with mass spectrometry sensitivity and scan speed have enabled more accurate, large-scale data analysis approaches that help answer many biological questions. GPU-based search engines designed to simultaneously execute many parallel instruction threads can reduce search times to the point where the search results can be converted into real-time input to drive tandem MS acquisition. This becomes an exciting part in our partnership with Bruker, as it will utilize the timsTOF Pro even more intelligently.'

Dr. Rohan Thakur, Executive Vice President of Life Sciences Mass Spectrometry at Bruker Daltonics, added: 'The IP2/GPU solution provides a software infrastructure that's amenable to supporting 'plug-in applications' from our third-party software partners that take advantage of high-performance cluster or cloud capabilities. We are committed to our strategy of open data file formats to facilitate community-driven software development, including our third-party partners through API access for the benefit of the timsTOF user community.'

Bruker will host a virtual scientific and trade press conference on Monday, June 1st, 2020, at 8:00 am CDT, including Bruker management and guest speaker Professor John Yates. Customers are invited to visit Bruker's ASMS 2020 Reboot virtual hospitality suite throughout the conference.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology.

Investor Contact: Miroslava Minkova Director, Investor Relations & Corporate Development T: +1 (978) 663-3660 x1479 E: investor.relations@bruker.com

Media Contact:

Petra Scheffer Bruker Daltonics Marketing & Communications T: +49 (421) 2205-2843 E: petra.scheffer@bruker.com

Disclaimer

Bruker Corporation published this content on 01 June 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 May 2020 00:44:07 UTC

Technical analysis trends BRUKER CORPORATION

Income Statement Evolution

Go here to see the original:
Bruker : Introduces Breakthrough MALDI-2 Source on timsTOF fleX, and Further Innovations in CCS-Enabled 4D Proteomics on timsTOF - Marketscreener.com

Read the Rest...

The Potential Impact of Coronavirus (COVID-19) for Releases New Report on the Global L-carnitine Tartrate Market – Cole of Duty

§ May 31st, 2020 § Filed under Nano Medicine Comments Off on The Potential Impact of Coronavirus (COVID-19) for Releases New Report on the Global L-carnitine Tartrate Market – Cole of Duty

Global L-carnitine Tartrate Market Growth Projection

The new report on the global L-carnitine Tartrate market is an extensive study on the overall prospects of the L-carnitine Tartrate market over the assessment period. Further, the report provides a thorough understanding of the key dynamics of the L-carnitine Tartrate market including the current trends, opportunities, drivers, and restraints. The report introspects the micro and macro-economic factors that are expected to nurture the growth of the L-carnitine Tartrate market in the upcoming years and the impact of the COVID-19 pandemic on the L-carnitine Tartrate . In addition, the report offers valuable insights pertaining to the supply chain challenges market players are likely to face in the upcoming months and solutions to tackle the same.

The report suggests that the global L-carnitine Tartrate market is projected to reach a value of ~US$XX by the end of 2029 and grow at a CAGR of ~XX% through the forecast period (2019-2029). The key indicators such as the year-on-year (Y-o-Y) growth and CAGR growth of the L-carnitine Tartrate market are discussed in detail in the presented report. This data is likely to provide readers an understanding of qualitative and quantitative growth prospects of the L-carnitine Tartrate market over the considered assessment period.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2657507&source=atm

The report clarifies the following doubts related to the L-carnitine Tartrate market:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2657507&source=atm

Segmentation of the L-carnitine Tartrate Market

Market Segment Analysis The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type, the L-carnitine Tartrate market is segmented into L-Carnitine Food Grade L-Carnitine Feed Grade L-Carnitine Pharmaceutical Grade

Segment by Application Animal Food Health Care Products Functional Drinks Medicine Others

Global L-carnitine Tartrate Market: Regional Analysis The L-carnitine Tartrate market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026. The key regions covered in the L-carnitine Tartrate market report are: North America U.S. Canada Europe Germany France U.K. Italy Russia Asia-Pacific China Japan South Korea India Australia Taiwan Indonesia Thailand Malaysia Philippines Vietnam Latin America Mexico Brazil Argentina Middle East & Africa Turkey Saudi Arabia U.A.E

Global L-carnitine Tartrate Market: Competitive Analysis This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.

The major players in global L-carnitine Tartrate market include: AIDP Biosint Chengda Pharmaceutical Hengtai Chemical Hongjing Chemical HuaYang Kangjian Chemical KangXin Chemical Koncepnutra Lonza Group Northeast Pharmaceutical

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2657507&licType=S&source=atm

Vital Information Enclosed in the Report

See the original post:
The Potential Impact of Coronavirus (COVID-19) for Releases New Report on the Global L-carnitine Tartrate Market - Cole of Duty

Read the Rest...

Coronavirus’ business impact: Spherical Activated Carbon Market 10-year Forecast and Trends Analysis Research Report – News Distinct

§ May 31st, 2020 § Filed under Nano Medicine Comments Off on Coronavirus’ business impact: Spherical Activated Carbon Market 10-year Forecast and Trends Analysis Research Report – News Distinct

The report on the Spherical Activated Carbon market provides a birds eye view of the current proceeding within the Spherical Activated Carbon market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Spherical Activated Carbon market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Spherical Activated Carbon market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025.

The Spherical Activated Carbon market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Spherical Activated Carbon market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2682266&source=atm

The major players profiled in this Spherical Activated Carbon market report include:

Segment by Type, the Spherical Activated Carbon market is segmented into 0.2-0.4mm Particle 0.4-0.6mm Particle 0.6-0.9mm Particle Above 0.9mm Particle Segment by Type, the Spherical Activated Carbon can be split into 0.2-0.4mm Particle, 0.4-0.6mm Particle, etc.

Segment by Application Gas and Waste Water Recovery Clean Room Air and Chemical Filters Polysilicon Production Process Water Treatment Medicine Other Segment by Application, the Spherical Activated Carbon market can be sub-segmented into several major Application, like Gas and Waste Water Recovery, Clean Room Air and Chemical Filters, etc. This section displays the market size by Application in 2020 and forecast to 2026. The CAGR (2020-2026) is based on the volume of Spherical Activated Carbon by Application and the overall market.

Global Spherical Activated Carbon Market: Regional Analysis The Spherical Activated Carbon market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026. The key regions covered in the Spherical Activated Carbon market report are: North America U.S. Canada Europe Germany France U.K. Italy Russia Asia-Pacific China Japan South Korea India Australia Taiwan Indonesia Thailand Malaysia Philippines Vietnam Latin America Mexico Brazil Argentina Middle East & Africa Turkey Saudi Arabia UAE

Global Spherical Activated Carbon Market: Competitive Analysis This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.

The major players in global Spherical Activated Carbon market include: Kureha Corporation Osaka Gas Chemical Group Kuraray Shanxi Xinhua Chemical

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2682266&licType=S&source=atm

Key Market Related Questions Addressed in the Report:

Important Information that can be extracted from the Report:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2682266&source=atm

Read this article:
Coronavirus' business impact: Spherical Activated Carbon Market 10-year Forecast and Trends Analysis Research Report - News Distinct

Read the Rest...

The impact of the coronavirus on the X-Ray Contrast Agents Market: Future Scenarios and Business Opportunity Analysis 2023 – 3rd Watch News

§ May 31st, 2020 § Filed under Nano Medicine Comments Off on The impact of the coronavirus on the X-Ray Contrast Agents Market: Future Scenarios and Business Opportunity Analysis 2023 – 3rd Watch News

Detailed Study on the Global X-Ray Contrast Agents Market

A recent market study throws light on some of the leading factors that are likely to influence the growth of the X-Ray Contrast Agents market in the upcoming decade. The well-researched market study touches upon the growth potential of various budding market players in the current X-Ray Contrast Agents market landscape. Moreover, established players, stakeholders, and investors can leverage the data in the report to formulate effective growth strategies.

As per the report, the X-Ray Contrast Agents market is forecasted to reach a value of ~US$XX by the end of 2029 and grow at a CAGR of ~XX% through the forecast period (2019-2029). The key dynamics of the X-Ray Contrast Agents market including the drivers, restraints, opportunities, and trends are thoroughly analyzed in the presented report.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2633017&source=atm

The Research Aims to Addresses the Following Doubts Pertaining to the X-Ray Contrast Agents Market

The report on the X-Ray Contrast Agents market provides a birds eye view of the current proceeding within the X-Ray Contrast Agents market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the X-Ray Contrast Agents market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the X-Ray Contrast Agents market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2633017&source=atm

X-Ray Contrast Agents Market Segmentation

Competitive Landscape

The competitive landscape section of the report elaborates on the recent developments and innovations introduced by prominent players in the X-Ray Contrast Agents market. The growth potential, revenue growth, product range, and pricing strategies of each market player in inspected in the report with precision.

End-use Industry Assessment

The report segments the X-Ray Contrast Agents market on the basis of end-use industry and offers a detailed understanding of the supply-demand ratio and consumption pattern of the X-Ray Contrast Agents in each end-use industry.

Market Segment Analysis The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type, the X-Ray Contrast Agents market is segmented into Medical Barium Sulfate Iodine

Segment by Application Hospitals Clinics Other

Global X-Ray Contrast Agents Market: Regional Analysis The X-Ray Contrast Agents market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026. The key regions covered in the X-Ray Contrast Agents market report are: North America U.S. Canada Europe Germany France U.K. Italy Russia Asia-Pacific China Japan South Korea India Australia Taiwan Indonesia Thailand Malaysia Philippines Vietnam Latin America Mexico Brazil Argentina Middle East & Africa Turkey Saudi Arabia U.A.E Global X-Ray Contrast Agents Market: Competitive Analysis This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019. The major players in global X-Ray Contrast Agents market include: Lantheus Medical Imaging Bracco SpA GE Healthcare Daiichi Sankyo Company Bayer Guerbet Group Hengrui Medicine BeiLu Pharmaceutical

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2633017&licType=S&source=atm

Essential Findings of the X-Ray Contrast Agents Market Report:

Link:
The impact of the coronavirus on the X-Ray Contrast Agents Market: Future Scenarios and Business Opportunity Analysis 2023 - 3rd Watch News

Read the Rest...

How Coronavirus Pandemic Will Impact Metal Oxide Nanomaterial Market 2025: Research By Top Manufacturers with Market Size,Market Growth, Competitive…

§ May 31st, 2020 § Filed under Nanomaterials Comments Off on How Coronavirus Pandemic Will Impact Metal Oxide Nanomaterial Market 2025: Research By Top Manufacturers with Market Size,Market Growth, Competitive…

Analysis of the Global Metal Oxide Nanomaterial Market

The report on the global Metal Oxide Nanomaterial market reveals that the market is expected to grow at a CAGR of ~XX% during the considered forecast period (2019-2029) and estimated to reach a value of ~US$XX by the end of 2029. The latest report is a valuable tool for stakeholders, established market players, emerging players, and other entities to devise effective strategies to combat the impact of COVID-19

Further, by leveraging the insights enclosed in the report, market players can devise concise, impactful, and highly effective growth strategies to solidify their position in the Metal Oxide Nanomaterial market.

Research on the Metal Oxide Nanomaterial Market Addresses the Following Queries

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2630144&source=atm

Competitive Landscape

The competitive landscape section offers valuable insights related to the business prospects of leading market players operating in the Metal Oxide Nanomaterial market. The market share, product portfolio, pricing strategy, and growth strategies adopted by each market player is included in the report. The major steps taken by key players to address the business challenges put forward by the novel COVID-19 pandemic is discussed in the report.

Regional Landscape

The regional landscape section provides a deep understanding of the regulatory framework, current market trends, opportunities, and challenges faced by market players in each regional market. The various regions covered in the report include:

End-User Assessment

The report bifurcates the Metal Oxide Nanomaterial market based on different end users. The supply-demand ratio and consumption volume of each end-user is accurately depicted in the report.

Market Segment Analysis The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type, the Metal Oxide Nanomaterial market is segmented into Aluminum Oxide Iron Oxide Titanium Dioxide Zinc Oxide Other

Segment by Application Electronics Personal Care Paints & Coatings Other

Global Metal Oxide Nanomaterial Market: Regional Analysis The Metal Oxide Nanomaterial market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026. The key regions covered in the Metal Oxide Nanomaterial market report are: North America U.S. Canada Europe Germany France U.K. Italy Russia Asia-Pacific China Japan South Korea India Australia Taiwan Indonesia Thailand Malaysia Philippines Vietnam Latin America Mexico Brazil Argentina Middle East & Africa Turkey Saudi Arabia U.A.E

Global Metal Oxide Nanomaterial Market: Competitive Analysis This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.

The major players in global Metal Oxide Nanomaterial market include: Sigma-Aldrich Corporation US Research Nanomaterials Inc. Nanophase Technologies Corporation EPRUI Nanoparticles & Microsphere Nanoshel LLC SkySpring Nanomaterials Inc. Baikowski SAS Advance NanoTek HAKUSUI TECH Sakai Chemical Zhengzhou Yongchang Shaanxi Sino-Academy Nano-Material Shanxi Four High Nano Technology

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2630144&source=atm

Essential Findings of the Metal Oxide Nanomaterial Market Report:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2630144&licType=S&source=atm

Continue reading here:

How Coronavirus Pandemic Will Impact Metal Oxide Nanomaterial Market 2025: Research By Top Manufacturers with Market Size,Market Growth, Competitive...

Read the Rest...

Complementary and Alternative Medicine Market: Industry Size, Share, Trends, Key Players and Forecast by 2026 – Cole of Duty

§ May 31st, 2020 § Filed under Quantum Medicine Comments Off on Complementary and Alternative Medicine Market: Industry Size, Share, Trends, Key Players and Forecast by 2026 – Cole of Duty

Los Angeles, United State: Complete study of the global Complementary and Alternative Medicine market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Complementary and Alternative Medicine industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Complementary and Alternative Medicine production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

The research study includes great insights about critical market dynamics, including drivers, restraints, trends, and opportunities. It also includes various types of market analysis such as competitive analysis, manufacturing cost analysis, manufacturing process analysis, price analysis, and analysis of market influence factors. It is a complete study on the global Complementary and Alternative Medicine market that can be used as a set of effective guidelines for ensuring strong growth in the coming years. It caters to all types of interested parties, viz. stakeholders, market participants, investors, market researchers, and other individuals associated with the Complementary and Alternative Medicine business.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart)https://www.qyresearch.com/sample-form/form/1698359/covid-19-impact-on-global-complementary-and-alternative-medicine-market

It is important for every market participant to be familiar with the competitive scenario in the global Complementary and Alternative Medicine industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key Players Mentioned in the Global Complementary and Alternative Medicine Market Research Report: , Columbia Nutritional, Herb Pharm, Herbal Hills, Helio USA, Deepure Plus, Nordic Naturals, Pure encapsulations, Iyengar Yoga Institute, John Schumachers Unity Woods Yoga Center, Yoga Tree, The Healing Company, Quantum Touch Complementary and Alternative Medicine

Global Complementary and Alternative Medicine Market Segmentation by Product:, Botanicals, Acupuncture, Mind, Body, and Yoga, Magnetic Intervention Complementary and Alternative Medicine

Global Complementary and Alternative Medicine Market Segmentation by Application: Direct Contact, E-training, Distance Correspondence

The report has classified the global Complementary and Alternative Medicine industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Complementary and Alternative Medicine manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Complementary and Alternative Medicine industry.

Additionally, the industry analysts have studied key regions including North America, Europe, Asia Pacific, Latin America, and Middle East and Africa, along with their respective countries. Here, they have given a clear-cut understanding of the present and future situations of the global Complementary and Alternative Medicine industry in key regions. This will help the key players to focus on the lucrative regional markets.

Key questions answered in the report:

Request for customization in Report:https://www.qyresearch.com/customize-request/form/1698359/covid-19-impact-on-global-complementary-and-alternative-medicine-market

Table od Content

1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by Complementary and Alternative Medicine Revenue 1.4 Market Analysis by Type 1.4.1 Global Complementary and Alternative Medicine Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Botanicals 1.4.3 Acupuncture 1.4.4 Mind, Body, and Yoga 1.4.5 Magnetic Intervention 1.5 Market by Application 1.5.1 Global Complementary and Alternative Medicine Market Share by Application: 2020 VS 2026 1.5.2 Direct Contact 1.5.3 E-training 1.5.4 Distance Correspondence 1.6 Coronavirus Disease 2019 (Covid-19): Complementary and Alternative Medicine Industry Impact 1.6.1 How the Covid-19 is Affecting the Complementary and Alternative Medicine Industry 1.6.1.1 Complementary and Alternative Medicine Business Impact Assessment Covid-19 1.6.1.2 Supply Chain Challenges 1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products 1.6.2 Market Trends and Complementary and Alternative Medicine Potential Opportunities in the COVID-19 Landscape 1.6.3 Measures / Proposal against Covid-19 1.6.3.1 Government Measures to Combat Covid-19 Impact 1.6.3.2 Proposal for Complementary and Alternative Medicine Players to Combat Covid-19 Impact 1.7 Study Objectives 1.8 Years Considered 2 Global Growth Trends by Regions 2.1 Complementary and Alternative Medicine Market Perspective (2015-2026) 2.2 Complementary and Alternative Medicine Growth Trends by Regions 2.2.1 Complementary and Alternative Medicine Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Complementary and Alternative Medicine Historic Market Share by Regions (2015-2020) 2.2.3 Complementary and Alternative Medicine Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porters Five Forces Analysis 2.3.5 Complementary and Alternative Medicine Market Growth Strategy 2.3.6 Primary Interviews with Key Complementary and Alternative Medicine Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top Complementary and Alternative Medicine Players by Market Size 3.1.1 Global Top Complementary and Alternative Medicine Players by Revenue (2015-2020) 3.1.2 Global Complementary and Alternative Medicine Revenue Market Share by Players (2015-2020) 3.1.3 Global Complementary and Alternative Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global Complementary and Alternative Medicine Market Concentration Ratio 3.2.1 Global Complementary and Alternative Medicine Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Complementary and Alternative Medicine Revenue in 2019 3.3 Complementary and Alternative Medicine Key Players Head office and Area Served 3.4 Key Players Complementary and Alternative Medicine Product Solution and Service 3.5 Date of Enter into Complementary and Alternative Medicine Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global Complementary and Alternative Medicine Historic Market Size by Type (2015-2020) 4.2 Global Complementary and Alternative Medicine Forecasted Market Size by Type (2021-2026) 5 Complementary and Alternative Medicine Breakdown Data by Application (2015-2026) 5.1 Global Complementary and Alternative Medicine Market Size by Application (2015-2020) 5.2 Global Complementary and Alternative Medicine Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Complementary and Alternative Medicine Market Size (2015-2020) 6.2 Complementary and Alternative Medicine Key Players in North America (2019-2020) 6.3 North America Complementary and Alternative Medicine Market Size by Type (2015-2020) 6.4 North America Complementary and Alternative Medicine Market Size by Application (2015-2020) 7 Europe 7.1 Europe Complementary and Alternative Medicine Market Size (2015-2020) 7.2 Complementary and Alternative Medicine Key Players in Europe (2019-2020) 7.3 Europe Complementary and Alternative Medicine Market Size by Type (2015-2020) 7.4 Europe Complementary and Alternative Medicine Market Size by Application (2015-2020) 8 China 8.1 China Complementary and Alternative Medicine Market Size (2015-2020) 8.2 Complementary and Alternative Medicine Key Players in China (2019-2020) 8.3 China Complementary and Alternative Medicine Market Size by Type (2015-2020) 8.4 China Complementary and Alternative Medicine Market Size by Application (2015-2020) 9 Japan 9.1 Japan Complementary and Alternative Medicine Market Size (2015-2020) 9.2 Complementary and Alternative Medicine Key Players in Japan (2019-2020) 9.3 Japan Complementary and Alternative Medicine Market Size by Type (2015-2020) 9.4 Japan Complementary and Alternative Medicine Market Size by Application (2015-2020) 10 Southeast Asia 10.1 Southeast Asia Complementary and Alternative Medicine Market Size (2015-2020) 10.2 Complementary and Alternative Medicine Key Players in Southeast Asia (2019-2020) 10.3 Southeast Asia Complementary and Alternative Medicine Market Size by Type (2015-2020) 10.4 Southeast Asia Complementary and Alternative Medicine Market Size by Application (2015-2020) 11 India 11.1 India Complementary and Alternative Medicine Market Size (2015-2020) 11.2 Complementary and Alternative Medicine Key Players in India (2019-2020) 11.3 India Complementary and Alternative Medicine Market Size by Type (2015-2020) 11.4 India Complementary and Alternative Medicine Market Size by Application (2015-2020) 12 Central & South America 12.1 Central & South America Complementary and Alternative Medicine Market Size (2015-2020) 12.2 Complementary and Alternative Medicine Key Players in Central & South America (2019-2020) 12.3 Central & South America Complementary and Alternative Medicine Market Size by Type (2015-2020) 12.4 Central & South America Complementary and Alternative Medicine Market Size by Application (2015-2020) 13 Key Players Profiles 13.1 Columbia Nutritional 13.1.1 Columbia Nutritional Company Details 13.1.2 Columbia Nutritional Business Overview and Its Total Revenue 13.1.3 Columbia Nutritional Complementary and Alternative Medicine Introduction 13.1.4 Columbia Nutritional Revenue in Complementary and Alternative Medicine Business (2015-2020)) 13.1.5 Columbia Nutritional Recent Development 13.2 Herb Pharm 13.2.1 Herb Pharm Company Details 13.2.2 Herb Pharm Business Overview and Its Total Revenue 13.2.3 Herb Pharm Complementary and Alternative Medicine Introduction 13.2.4 Herb Pharm Revenue in Complementary and Alternative Medicine Business (2015-2020) 13.2.5 Herb Pharm Recent Development 13.3 Herbal Hills 13.3.1 Herbal Hills Company Details 13.3.2 Herbal Hills Business Overview and Its Total Revenue 13.3.3 Herbal Hills Complementary and Alternative Medicine Introduction 13.3.4 Herbal Hills Revenue in Complementary and Alternative Medicine Business (2015-2020) 13.3.5 Herbal Hills Recent Development 13.4 Helio USA 13.4.1 Helio USA Company Details 13.4.2 Helio USA Business Overview and Its Total Revenue 13.4.3 Helio USA Complementary and Alternative Medicine Introduction 13.4.4 Helio USA Revenue in Complementary and Alternative Medicine Business (2015-2020) 13.4.5 Helio USA Recent Development 13.5 Deepure Plus 13.5.1 Deepure Plus Company Details 13.5.2 Deepure Plus Business Overview and Its Total Revenue 13.5.3 Deepure Plus Complementary and Alternative Medicine Introduction 13.5.4 Deepure Plus Revenue in Complementary and Alternative Medicine Business (2015-2020) 13.5.5 Deepure Plus Recent Development 13.6 Nordic Naturals 13.6.1 Nordic Naturals Company Details 13.6.2 Nordic Naturals Business Overview and Its Total Revenue 13.6.3 Nordic Naturals Complementary and Alternative Medicine Introduction 13.6.4 Nordic Naturals Revenue in Complementary and Alternative Medicine Business (2015-2020) 13.6.5 Nordic Naturals Recent Development 13.7 Pure encapsulations 13.7.1 Pure encapsulations Company Details 13.7.2 Pure encapsulations Business Overview and Its Total Revenue 13.7.3 Pure encapsulations Complementary and Alternative Medicine Introduction 13.7.4 Pure encapsulations Revenue in Complementary and Alternative Medicine Business (2015-2020) 13.7.5 Pure encapsulations Recent Development 13.8 Iyengar Yoga Institute 13.8.1 Iyengar Yoga Institute Company Details 13.8.2 Iyengar Yoga Institute Business Overview and Its Total Revenue 13.8.3 Iyengar Yoga Institute Complementary and Alternative Medicine Introduction 13.8.4 Iyengar Yoga Institute Revenue in Complementary and Alternative Medicine Business (2015-2020) 13.8.5 Iyengar Yoga Institute Recent Development 13.9 John Schumachers Unity Woods Yoga Center 13.9.1 John Schumachers Unity Woods Yoga Center Company Details 13.9.2 John Schumachers Unity Woods Yoga Center Business Overview and Its Total Revenue 13.9.3 John Schumachers Unity Woods Yoga Center Complementary and Alternative Medicine Introduction 13.9.4 John Schumachers Unity Woods Yoga Center Revenue in Complementary and Alternative Medicine Business (2015-2020) 13.9.5 John Schumachers Unity Woods Yoga Center Recent Development 13.10 Yoga Tree 13.10.1 Yoga Tree Company Details 13.10.2 Yoga Tree Business Overview and Its Total Revenue 13.10.3 Yoga Tree Complementary and Alternative Medicine Introduction 13.10.4 Yoga Tree Revenue in Complementary and Alternative Medicine Business (2015-2020) 13.10.5 Yoga Tree Recent Development 13.11 The Healing Company 10.11.1 The Healing Company Company Details 10.11.2 The Healing Company Business Overview and Its Total Revenue 10.11.3 The Healing Company Complementary and Alternative Medicine Introduction 10.11.4 The Healing Company Revenue in Complementary and Alternative Medicine Business (2015-2020) 10.11.5 The Healing Company Recent Development 13.12 Quantum Touch 10.12.1 Quantum Touch Company Details 10.12.2 Quantum Touch Business Overview and Its Total Revenue 10.12.3 Quantum Touch Complementary and Alternative Medicine Introduction 10.12.4 Quantum Touch Revenue in Complementary and Alternative Medicine Business (2015-2020) 10.12.5 Quantum Touch Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Disclaimer 15.3 Author Details

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

Follow this link:

Complementary and Alternative Medicine Market: Industry Size, Share, Trends, Key Players and Forecast by 2026 - Cole of Duty

Read the Rest...

Read the main factors affecting complementary and alternative medicine market to achieve a constant growth in this segment – Cole of Duty

§ May 31st, 2020 § Filed under Quantum Medicine Comments Off on Read the main factors affecting complementary and alternative medicine market to achieve a constant growth in this segment – Cole of Duty

The global complementary and alternative medicine market size was projected at USD 69.2 billion in 2019, registering a CAGR of 19.9% over the forecast period.

For the treatment of chronic ailments, long-term pain among others and also for additional vitamins and other dietary supplements of regular diet, complementary and alternative forms of therapy are being used. Further, during the forecast period the market is probable to grow with considerable increment in the costs of conventional medicine and inclination against body wellness instead of pharmaceutical cure.

Download COVID-19 Impact Complementary and Alternative Medicine Market Report Sample

https://www.abstractmarketresearch.com/report/complementary-and-alternative-medicine-market#request-sample

Abstract Market Research has presented a statistical data to its extensive repository titled complementary and alternative medicine market. The study comprises different segments and sub-segments such as type, size, applications, and end-users. One of the many distinctive features of the report is it provides an analytical study of the global complementary and alternative medicine market based on various growth influencing factors. Primary and secondary research techniques have also been used by analysts of the report to study the market.

The prominent players of Complementary And Alternative Medicine Market are Columbia Nutritional Inc.; Herb Pharm; Herbal Hills; Helio USA Inc.; Deepure Plus; Nordic Naturals; Pure encapsulations, Inc.; and other wellness institutes like Iyengar Yoga Institute; John Schumachers Unity Woods Yoga Center; Yoga Tree; The Healing Company; and Quantum Touch Inc.

Ask a [emailprotected] https://www.abstractmarketresearch.com/report/complementary-and-alternative-medicine-market#request-discount

Widespread global regions such as North America, Latin America, Europe, Asia-Pacific, Africa, and India have also been examined in order to get a better understanding of the competitive landscape. The research report thus inspects market size, pricing structures, and shares. The current development patterns of various successful industries have also been mentioned in order to understand effective business strategies. In order to get a stronger and effective business outlook, the report also studies several internal and external factors. These can be attributed as market restraints and propellers. Additionally, the report also offers insightful data which helps to formulate the best strategies for both established key players as well as for new market entrants. Furthermore, the study discusses the challenges and risks experienced by several sellers as well as buyers. To discover the global opportunities that are shaping the global complementary and alternative medicine market.

Request for [emailprotected] https://www.abstractmarketresearch.com/report/complementary-and-alternative-medicine-market#customization

Complementary And Alternative Medicine Market Key Segments:

Intervention Outlook (Revenue, USD Billion, 2019- 2027) o Botanicals o Ayurveda o Naturopathy o Homeopathy o Acupuncture o Mind, Body, and Yoga o Yoga o Meditation o Energy Healing o Chakra Healing o Hypnotherapy o Magnetic Intervention

Distribution Method Outlook (Revenue, USD Billion, 2019- 2027) o Direct Contact o E-training o Distance Correspondence

Regional Outlook (Revenue, USD Billion, 2019-2027) o North America o U.S. o Canada

o Europe o Austria o Belgium o Denmark o France o Germany o Ireland o Norway o Netherlands o Spain o Sweden o Switzerland o U.K.

o Asia Pacific o Australia o China o Hong Kong o India o Japan o New Zealand o Singapore

o Latin America o Argentina o Brazil o Mexico

o MEA o Israel o South Africa o UAE

See more here:

Read the main factors affecting complementary and alternative medicine market to achieve a constant growth in this segment - Cole of Duty

Read the Rest...

Securing Medical Technology in the Age of COVID-19 – Infosecurity Magazine

§ May 30th, 2020 § Filed under Nano Medicine Comments Off on Securing Medical Technology in the Age of COVID-19 – Infosecurity Magazine

Consider the miracle of a pacemaker that promotes heartbeat regularity or an insulin pump that ensures a diabetics pancreatic function both are devices operated by a distant network. Now, imagine if those networks were to fail. Particularly in the age of COVID-19, technology experts are feeling the pressure to develop new strategies to tackle healthcare challenges. Cyber threats in the field of medical technology range from hacking of IoT medical devices, such as insulin pumps and pacemakers, to the PHI of cardiac arrest patients being locked by ransomware attackers, thus preventing timely treatment of patients in critical condition due to heart attack.

While thousands of patients utilize such medical devices, the security of these systems lies with the networks remotely powering the device. Moreover, nanomedicine or the use of nantotechnology for healthcare purposes such as eradication of cancer cells also relies on such distant networks. Like any computer network, SCADA systems face risks from a variety of cyber-attacks.

Recently, Dr. Gregory Carpenter, a Cyber Epidemiologist at KnowledgeBridge International Inc., has revealed his teams investigation results, including the discovery that 23 of the 25 bio-nano carrier networks tested were vulnerable to basic DDoS attacks, as well as other legacy threats such as outdated and unpatched systems exposed to zero-day attacks.

The operational nature of SCADA especially in healthcare remains highly collaborative, with medical staff sharing data amongst themselves as well as hospital IT teams sharing information with cloud brokers and providers. Indeed, as more medical organizations migrate to the cloud, such data sharing coupled with the lack of visibility inherent to the cloud environment poses many risks.

As the attack surface increases l with both medical IoT and PHIs exposure to the cloud, hospitals and medical device providers could benefit from ensuring that patient information is encrypted and their cloud providers have secure defenses in place against denial of service attacks.

In the area of cloud security, healthcare organizations should e bear in mind that while their cloud service providers control the physical security of the servers in their data centers, as cloud customers, the organizations themselves hold responsibility for encrypting data in transit. Therefore, all data whether PHI or related to the operations of medical technology should remain top priority for in-transit security.

In-transit encryption best practices involve the key elements of defining data protection requirements, implementing secure certificate and stored key management, automating data leak detection and authenticating network communications via IPSec or TLS protocols. Such steps to enforcement will help assure that data moving between the cloud provider and healthcare entity endpoint remains secure.

A helpful starting point might entail configuring load balancers to only interact with HTTPS traffic in order to promote encrypted movement of data between the host organization and cloud service provider. Another solution to in-transit security lies in the use of VPN between the cloud provider and healthcare customer. Additionally, both provider and customer must maintain cognizance surrounding faults in availability, in terms of impact to quality of care as well as implications regarding the potential underlying context of such events.

In particular, phishing campaigns have often worked in parallel to larger-scale attacks such as DDoS, in an attempt to infiltrate the target network while security teams focus on the availability-based incident. Therefore, healthcare senior management and IT personnel who observe compromise attempts via network intrusion detection data can help safeguard against a breach by warning all employees to remain vigilant regarding potential phishing emails.

As email-based attacks have especially targeted the healthcare industry amidst the recent COVID-19 crisis, medical professionals and their patients stand to gain the most from hospital management and practitioners learning how to avoid such correlated threats.

To this effect, security awareness training provides an optimal defense against the possibility for data compromise by human error. With fewer physicians and hospital administrators falling victim to scareware and other malicious email-based activity, the attack vector shrinks for cyber-criminals looking to capitalize on the panic over the current global pandemic.

Furthermore, network administrators in the healthcare space can do their part by tightly monitoring infrastructure for any penetration attempt. A place to begin might be examining signs of botnet activity and other availability-based attacks with phishing attempts that occur within a similar timeframe of around 24 hours or fewer. As soon as a security team detects a compromise, all associated medical devices must be immediately remotely deactivated.

Perhaps most importantly, providers of biotechnology as well as hospital services must maintain transparency with all customers and patients regarding any suspected or successful breaches. After all, the individuals receiving treatment in these instances face the highest risk, as any successful attacker holds the power to not only access PHI, but potentially also to hack into a medical device on which a human life might depend.

Sarah Katz is an author working in information security at NASA. Since graduating from UC Berkeley, she has published various pieces in research and science fiction, primarily surrounding the intersection of medicine and technology. Most recently, she has founded Cysec Health, a nonprofit group of cybersecurity volunteers supporting women's health organizations amid the COVID-19 pandemic.

Originally posted here:
Securing Medical Technology in the Age of COVID-19 - Infosecurity Magazine

Read the Rest...

Nanobiotix Announces Positive First Results From Phase I Expansion in Locally Advanced Head and Neck Cancer at ASCO 2020 – Press Release – Digital…

§ May 30th, 2020 § Filed under Nano Medicine Comments Off on Nanobiotix Announces Positive First Results From Phase I Expansion in Locally Advanced Head and Neck Cancer at ASCO 2020 – Press Release – Digital…

PARIS & CAMBRIDGE, Mass.--(Business Wire)--Regulatory News:

NANOBIOTIX (Paris:NANO)(Euronext: NANO - ISIN: FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced new data from the expansion part of its phase I trial, evaluating the potential of first-in-class NBTXR3 activated by radiation therapy to improve treatment outcomes for elderly patients with locally advanced head and neck cancer ineligible for chemotherapy or intolerant to cetuximab. The data were published as part of the virtual scientific program at the 2020 annual meeting of the American Society for Clinical Oncology (ASCO).

Study 102: A phase I trial of hafnium oxide nanoparticles activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients

Authors: Christophe Le Tourneau, Valentin Calugaru, Edith Borcoman, Victor Moreno, Emiliano Calvo, Xavier Liem, Sebastien Salas, Bernard Doger, Olivier Choussy, Maria Lesnik, Xavier Mirabel, Nathalie Badois, Samar Krhili, Josefin Blomkvist, Nicolas Fakhry, Stphanie Wong-Hee-Kam, Caroline Hoffmann.

J Clin Oncol 38: 2020 (suppl; abstr 6573). DOI: 10.1200/JCO.2020.38.15_suppl.6573.

Abstract Number: 6573

Study Design

After reporting promising early signs of activity from the dose escalation part of its phase I trial evaluating the safety and feasibility of NBTXR3 activated by radiation therapy in elderly patients with locally advanced head and neck squamous cell carcinoma (HNSCC), the Company launched an expansion cohort to confirm results and observed trends with a larger population treated at the recommended dose. This part of the study is expected to recruit a total of 44 evaluable patients. To date, 40 patients have been recruited, 30 of whom are evaluable for efficacy and are included in the data presented at ASCO 2020.

Topline Results

As previously announced, in the dose escalation part of the study NBTXR3 activated by radiation therapy was safe and well tolerated. The recommended phase 2 dose (RP2D) was determined to be 22% of baseline tumor volume. Among 16 evaluable patients, injected lesion complete response rate was 56% and overall objective response rate was 69%.

Regarding the new, expansion part data, analysis of 40 patients dosed showed that NBTXR3 activated by radiation therapy remains safe and well tolerated. In terms of efficacy, for the 30 evaluable patients, investigators observed, at a median time of 5 months after NBTXR3 injection, an overall objective response rate of 83% and an overall complete response rate of 43% and objective response rate of the primary tumor (target lesion) of 83% with a complete response rate of the primary tumor of 60%. The safety profile was consistent with the dose escalation part and the efficacy data improved (i.e. an increase in overall objective response rate from 69% in the dose escalation part to 83% in the dose expansion part).

In the safety population (all treated patients, N=40), three serious adverse events (SAEs) related to NBTXR3 were observed (0.7% of all AEs), comprising one case each of: Grade 4 tumor hemorrhage also related to radiotherapy, Grade 3 mucosal inflammation and Grade 2 swollen tongue also related to the injection procedure. Two SAEs related to the injection procedure were reported (0.5% of all AEs), comprising: two cases of swollen tongue, of which one was Grade 2 and also related to NBTXR3, and one was Grade 4. The radiotherapy-associated safety profile was as expected with the most frequently occurring AEs being stomatitis and skin injury. Three deaths due to AEs related to radiotherapy and other causes were observed. Four other patients died of non-oncologic or non-toxicity-related reasons.

Next Steps in Head and Neck Cancer

The expansion part of the phase I trial will continue to recruit until reaching 44 evaluable patients. In parallel, subject to the FDAs pending review, the Company intends to globally launch a pivotal phase III trial. In the planned phase III trial, a futility analysis is expected 18 months after the first patient is randomized, and an interim analysis of progression-free survival (PFS) is expected at 24-30 months.

NBTXR3 for the treatment of locally advanced HNSCC patients who are not eligible for platinum-based chemotherapy received Fast Track designation from the FDA in February 2020. Fast Track designation is a process designed to facilitate the development and accelerate the review of drugs for serious conditions that have the potential to address unmet medical needs. The purpose is to expedite the availability of new treatment options for patients.

About NBTXR3

NBTXR3 is a first-in-class product designed to destroy tumors through physical cell death when activated by radiotherapy. NBTXR3 has a high degree of biocompatibility, requires one single administration before the first radiotherapy treatment session, and has the ability to fit into current worldwide radiation therapy standards of care. The physical mode of action of NBTXR3 makes it applicable across solid tumors.

NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Promising results have been observed in the phase I trial regarding local control. In the United States, the Company has started the regulatory process to commence a phase III clinical trial in locally advanced head and neck cancers.

Nanobiotix is also running an Immuno-Oncology development program. The Company has launched a Phase I clinical trial of NBTXR3 activated by radiotherapy in combination with anti-PD-1 checkpoint inhibitors in locoregional recurrent (LRR) or recurrent and metastatic (R/M) HNSCC amenable to re-irradiation of the HN and lung or liver metastases (mets) from any primary cancer eligible for anti-PD-1 therapy.

Other ongoing NBTXR3 trials are treating patients with hepatocellular carcinoma (HCC) or liver metastases, locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and pancreatic cancer. The Company has a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center (initially expected to support 9 new clinical trials in the United States) to evaluate NBTXR3 across several cancer types.

About NANOBIOTIX: http://www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France, with a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Nanobiotix approved by the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.20-010 on May 12, 2020 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200529005528/en/

Nanobiotix Communications Department Brandon Owens +1 (617) 852-4835 contact@nanobiotix.com

Investor Relations Department Ricky Bhajun +33 (0)1 79 97 29 99 investors@nanobiotix.com

Media Relations France TBWA Corporate Pauline Richaud + 33 (0) 437 47 36 42 Pauline.richaud@tbwa-corporate.com

US RooneyPartners Marion Janic +1 (212) 223-4017 mjanic@rooneyco.com

Go here to read the rest:
Nanobiotix Announces Positive First Results From Phase I Expansion in Locally Advanced Head and Neck Cancer at ASCO 2020 - Press Release - Digital...

Read the Rest...

UW researcher invents groundbreaking microbiological gout remedy | Current Edition – Wyoming Tribune

§ May 30th, 2020 § Filed under Genetically Modified Humans Comments Off on UW researcher invents groundbreaking microbiological gout remedy | Current Edition – Wyoming Tribune

Dr. Christoph Geisler hadnt thought much about gout one way or another until his former boss had a debilitating attack, which prompted the microbiologist to do a little investigating. What he found was not only was the affliction incredibly painful, but there were also no good cures.

Now, less than a year later, the former chemical engineer turned molecular biologist has turned his curiosity into a full-time career and business. Hes now getting close to launching the first genetically engineered probiotic designed to tackle gout by targeting the gut. His patent-pending probiotic supplement called Krystalase contains microbes specifically engineered to address the root cause of gout.

Geisler, a former doctorate student at the University of Wyoming, is originally from the Netherlands. He founded his company, Theraneutrics, in 2018 and was one of three new innovative companies to win UWs prestigious Microbial Ecology Collaborative Startup Launchpad (MECSL) award in April. Along with the designation, the award also includes $25,000 in seed capital funded by the National Science Foundation and Wyoming EPSCoR. This money is split among the three winners, including Laramie-based AsimicA and Livestock Wx, a Casper company founded by Chad McNutt to provide weather information for livestock producers.

As one of the winners, Geisler not only won seed funding for his business, but also was affirmed in the promise of his idea. He plans to use the money to help develop his prototype strain, which is currently in the research and development phase and thus far demonstrates proof of principle in a test tube.

Although seemingly simple in theory, his genetically modified strain of yeast works as a probiotic to break down the uric acid that humans are unable to metabolize. The human body makes uric acid as a byproduct, and if levels get too high, it can start to form long, thin needle-like crystals in joints. The result is gout, with pain that Geisler describes as one of the worst imaginable. And though uric acid is produced in cells of every part of the body, humans and apes unlike other mammals and organisms are unable to metabolically break down the poorly soluble substance.

Think of humans as mutants that dont have the gene to degrade uric acid, he said. In healthy humans, it ends up excreted (though urine), but it cant be broken down by our bodies.

Until now, Geisler explained, despite the prevalence of gout in the United States and beyond, there hasnt been a new cure invented for the past 40 years. People tend to think of gout as a 19th century ailment, he added, but its actually becoming much more common because of the obesity epidemic, and heavy dairy and meat consumption. There are basically two commonly prescribed remedies created by big pharma, both of which are rife with detrimental side effects because they go directly into the bloodstream, he explained.

His probiotic has been engineered to target and break down uric acid in the gut to prevent it from being reabsorbed in the bloodstream. This eliminates it from the body and stops gout attacks by preventing uric acid crystals from forming. There are many other supplements, typically plant-based, that are marketed towards gout, Geisler mentioned. This includes cherry extract, which decreases inflammation and helps with the pain. However, none of these supplements actually target the root cause of gout, Geisler said, and many rely on a placebo effect: They create the illusion of actually working, when, in fact, many people just learn to live with the pain.

Geisler, who thus far is an inventor on four U.S. patents, is encouraged by the success of his probiotic thus far, and plans to begin testing it on mice as Theraneutrics enters the next phase of product testing. Due to the time required and expense of doing multiple trials to earn Food and Drug Administration approval, Geisler plans to market Krystalase as a supplement, which cuts up to 10 years off the time required to bring a product to market.

Unlike the costly price of the most effective anti-gout drugs on the market (up to $17,000 every two to four weeks), Krystalase is designed to be affordable at about $3 per day (or roughly $90 a month), with no side effects or need for expensive health insurance. Because it is genetically modified, as opposed to plant-based organic, he recognizes his market will likely not compete with organic supplements. Instead, this puts him in a category of his own as the first probiotic specifically designed to tackle gout. He expects to optimize the genetic circuits and complete animal trials over the next year, at which point he thinks the product will be getting ready to hit markets.

Why nobody until now has thought to tackle gout on a metabolic level is a question that he cant answer.

Somebody has to be the first to come up with the idea, right? he said with a laugh.

Traditionally, gout research has been confined to designing new drugs that target the same mechanism, and therefore are likely to be no more effective than existing drugs, with similar side effects, Geisler said. On top of that, he added, the phrase genetically modified, has been demonized, making it scary to many. Advancements in gene modification technology, however, have come a long way in the past two decades, he noted, making such tools much more accessible for researchers like him.

Mainly, he said, hes happy to work on creating a product that has the potential of bringing relief to a large body of patients currently suffering from such a painful ailment.

Once he successfully brings Krystalase to market, who knows where his next inspiration will take him? Maybe hell accidentally run into another medical condition for which theres no good cure. Necessity, after all, as he pointed out, is the mother of all invention.

View original post here:

UW researcher invents groundbreaking microbiological gout remedy | Current Edition - Wyoming Tribune

Read the Rest...

Ethicists: We need more flexible tools for evaluating gene-edited food – The Conversation US

§ May 30th, 2020 § Filed under Genetically Modified Humans Comments Off on Ethicists: We need more flexible tools for evaluating gene-edited food – The Conversation US

Is there now a way to genetically engineer crops to create food that people can confidently consider natural?

Gene-editing technology sounds like it might offer this possibility. By altering an organisms genetic material, or genome, without introducing genes from other species, advocates of genome editing argue the technique can sidestep most of the difficult ethical and regulatory challenges plaguing organisms with added transgenes, which are genes from other species. Some even argue these cisgenic products are natural enough to count as organic.

As ethicists specializing in how technology alters human-nature relations, we can understand why advocates see the ethics this way. If crossing species lines is the measure of whether a technique counts as natural or not, then genome editing appears to have the potential to pass a naturalness test.

Genome editing, its boosters say, can make changes that look almost evolutionary. Arguably, these changes could have happened by themselves through the natural course of events, if anyone had the patience to wait for them. Conventional breeding for potatoes resistant to late blight is theoretically possible, for example, but it would take a lot of time.

Although we understand the potential advantages of speed, we dont think an ethics hinging on the idea of cisgenesis is adequate. We propose a better ethical lens to use in its place.

Our work is part of a four-year project funded by the Norwegian Research Council scrutinizing how gene editing could change how we think about food. The work brings together researchers from universities and scientific institutes in Norway, the U.K. and the U.S. to compare a range of techniques for producing useful new crops.

Our project is not focused on the safety of the crops under development, something that obviously requires concerted scientific investigation of its own. Although the safety of humans and the health of the environment is ethically crucial when developing new foods, other ethical issues must also be considered.

To see this, consider how objections against genetically modified organisms go far beyond safety. Ethical issues around food sovereignty range broadly across farmer choice, excess corporate power, economic security and other concerns. Ethical acceptability requires a much higher bar than safety alone.

Although we believe gene editing may have promise for addressing the agricultural challenges caused by rising global populations, climate change and the overuse of chemical pesticides, we dont think an ethical analysis based entirely on crossing species lines and naturalness is adequate.

It is already clear that arguing gene-edited food is ethical based on species lines has not satisfied all of gene editings critics. As Ricarda Steinbrecher, a molecular biologist cautious about gene editing, has said, Whether or not the DNA sequences come from closely related species is irrelevant, the process of genetic engineering is the same, involving the same risks and unpredictabilities, as with transgenesis.

Comments of this kind suggest talking about species lines is an unreliable guide. Species and subspecies boundaries are notoriously infirm. Charles Darwin himself conceded in Origin of Species, I look at the term species, as one arbitrarily given for the sake of convenience to a set of individuals closely resembling each other.

The 2005 edition of the Mammal Species of the World demonstrated this arbitrariness by collapsing all 12 subspecies of American cougars down to one Puma concolor cougar overnight. In 2017, the Cat Classification Task Force revised the Felidae family again.

If species lines are not clear, claiming naturalness based on not crossing species lines is, in our view, a shaky guide. The lack of clarity matters because a premature ethical green light could mean a premature regulatory green light, with broad implications for both agricultural producers and consumers.

We think a more reliable ethical measure is to ask about how a technique for crop breeding interferes with the integrity of the organism being altered.

The term integrity already has application in environmental ethics, ecology, cell biology, interhuman ethics, organic agriculture and genetics.

A unifying theme in all these domains is that integrity points toward some kind of functional wholeness of an organism, a cell, a genome or an ecological system. The idea of maintaining integrity tracks a central intuition about being cautious before interfering too much with living systems and their components.

The integrity lens makes it clear why the ethics of gene editing may not be radically different from the ethics of genetic modification using transgenes. The cell wall is still penetrated by the gene-editing components. The genome of the organism is cut at a site chosen by the scientist, and a repair is initiated which (it is hoped) will result in a desired change to the organism. When it comes to the techniques involved with gene editing a crop or other food for a desired trait, integrity is compromised at several levels and none has anything to do with crossing species lines. The integrity lens makes it clear the ethics is not resolved by debating naturalness or species boundaries.

Negotiation of each others integrity is a necessary part of human-to-human relations. Adopted as an ethical practice in the field of biotechnology, it might provide a better guide in attempts to accommodate different ethical, ecological and cultural priorities in policymaking. An ethic with a central place for discussion of integrity promises a framework that is both more flexible and discerning.

As new breeding techniques create new ethical debates over food, we think the ethical toolbox needs updating. Talking about crossing species lines simply isnt enough. If Darwin had known about gene editing, we think he would have agreed.

[Deep knowledge, daily. Sign up for The Conversations newsletter.]

Visit link:

Ethicists: We need more flexible tools for evaluating gene-edited food - The Conversation US

Read the Rest...

This Shavuot, Have Another Slice of Grasshopper Cheesecake or Be Brave Enough to Try a Real Insect – CTech

§ May 30th, 2020 § Filed under Genetically Modified Humans Comments Off on This Shavuot, Have Another Slice of Grasshopper Cheesecake or Be Brave Enough to Try a Real Insect – CTech

In Israel, the Jewish harvest holiday of Shavuot, also known as Pentecost, which is celebrated this week. is dominated by cheese and cheesecake. But this year, even observant Jews, separating dairy and meat products, might want to consider adding some novel parve grasshopper meat to their dairy spread.

Notably, the United Nations Food and Agriculture Organization (FAO) has been a longstanding supporter of cultivating insects as an alternative source of protein. However, introducing new protein sources, even from resources that have been around for a long time, like bugs, requires compliance with sometimes onerous regulatory oversight.

For example, the European Union (EU), which is infamously terrified of genetically modified (GMO) food products, has a special set of new regulations for novel foods. As per the EU rules, novel foods are defined as "food that had not been consumed to a significant degree by humans in the EU before May 15, 1997." Insects clearly fall under this legal definition.

The novel food regulatory process is also designed to allow foods that are otherwise eaten in other countries, for example, traditional foods, like grasshopper, to be brought into the EU. Currently, the process is notoriously long and expensive, and, to date, only four traditional foods have been authorized since the law's inception in 2018.

As of last month, however, it was reported that the European Food Safety Authority (EFSA) was set to rule on allowing insect-based foods such as those containing parts of or whole mealworms, locusts, crickets, and grasshoppers to be readily available across the continent by the fall of 2020.

The U.S. insect food industry has been even more stifled, heretofore lacking any standard system for regulating insects as food. Allegedly, it has focused more on their negative aspects, regulating, for example, insect parts in food as filthand not on their potential as edible foods via certified Good Manufacturing Practices (cGMP).

Until such time as entomophagy becomes mainstream, the aforementioned fast food industry is at least trying to do its part in dealing with the coronavirus (Covid-19) pandemic. Burger King, for example, recently announced it would be including extra onions in its Whoppers in Italy in the hope that the resulting bad breath will provide that needed extra impetus for keeping social distancing guidelines.

Edible insects, like other technologies and ideas that have long sat at the cusp of broad social acceptance, may have found their opportunity to go mainstream during the current crisis. There is a growing push to use the global pandemic as an opportunity to reset some of our bad habits and help promote wallflower notions, including telemedicine, distance learning, and even universal basic income.

The World Economic Forum (WEF), for example, sees the crisis as an occasion to "to redesign a sustainable, inclusive economy, revitalizing industry, preserving vital biodiversity systems and tackling climate change." Effectively, the WEF sees this as an opportunity to push through the European Green New Deal that was proposed just prior to the first reports of the pandemic in December.

Under this agenda, Europe's "greener, more resilient and inclusive future" would find the use of alternative, affordable, and clean protein sources to be especially appealing.

But not everything at the end of the pandemic will be green. NASA's iconic pumpkin-colored flight suits will be replaced this week with Hollywood-designed, retro white suits that will be worn by the first two astronauts to arrive at the International Space Station (ISS) on a private rocket. The suits design has already proven its mettle in two previous launches with Starman on Elon Musk's orbiting Tesla and Ripley, the female test dummy, in an early test of the Dragon Crew capsule.

Many look forward to seeing NASA's real human astronauts, Bob Behnken and Doug Hurley, arrive at the ISS via SpaceX's Crew Dragon capsule, bedecked in their new white suits on their historic mission, if all goes well, just as Shavuot starts on Thursday.

Behnken and Hurley however, wont be the only ones who will have the opportunity to experience Shavuot in space. Late last week, Japans space agency JAXA, in conjunction with Japanese robotics startup GITAI Inc. reportedly sent a telepresence robot, effectively a space avatar or robonaut, to the ISS. This device will allow select earth-bound individuals to begin to appreciate what it is like to spend time on the ISS, and is designed, ironically, just as we are introducing new ways to launch humans outside of earth, to reduce our reliance on a human presence in space.

Behnken and Hurley also won't be the only people wearing white this weekend. While Americans already traditionally started wearing white as part of their formal attire on Memorial Day, this past Monday, many Israelis will likely be festooned in their whites this coming Shavuot, while enjoying the holidays white night (all-nighter) learning events.

Although NASA, which consideredincorporating insects (as of 1947, the first animals in space) into its space-cuisine as far back as 1981, will likely not be feeding its new ISS guests any grasshoppers this Shavuot, maybe people down here on earth might be bold enough to do so. And, if you still cannot stomach the real deal, at least enjoy the long-standing Shavuot staple, the green-hued grasshopper cheesecake.

Dov Greenbaum is a director at the Zvi Meitar Institute for Legal Implications of Emerging Technologies, at Israeli academic institute IDC Herzliya.

Excerpt from:

This Shavuot, Have Another Slice of Grasshopper Cheesecake or Be Brave Enough to Try a Real Insect - CTech

Read the Rest...

« Older Entries Newer Entries »



Page 22«..10..21222324..3040..»